Podcasts about ckd

Health care executive and patient advocate Aja Best discusses her article, "How early CKD diagnosis can save lives: a transplant survivor's journey." She shares her harrowing personal experience with a delayed diagnosis of IgA nephropathy during pregnancy, which led to a challenging path through dialysis and ultimately to a life-saving kidney transplant. Aja highlights the often-silent progression of chronic kidney disease (CKD), a growing global health crisis, and points to critical gaps in the health care system that prevent timely intervention. The conversation explores the importance of early screening, proactive and coordinated care, the potential of technology and predictive analytics to improve patient outcomes, and the power of patient advocacy. Aja passionately calls for systemic changes and greater awareness to ensure others don't face the same missed opportunities she did. The key takeaway is: Early CKD detection through routine screening and a more integrated, patient-centered health care approach can significantly alter disease progression, improve lives, and reduce the burden of this widespread condition. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Modern medicine has made significant strides in managing chronic diseases, yet many elderly patients with multiple conditions continue to deteriorate under standard care. Conventional therapies often overlook the root causes of chronic degeneration, such as oxidative stress, mitochondrial dysfunction, toxin accumulation, and nutritional deficiencies. IntegrativeOrthomolecular Medicine (IOM) offers a solution-oriented framework that emphasizes restoring biochemical balance through therapeutic nutrition, detoxification, metabolic support, and lifestyle interventions. This case study illustrates the practical application and impressive results of an IOM protocol in an elderly woman with T2DM, CKD with renal insufficiency, Parkinsonism, and recurrent infections.In this episode George discusses the case study of a 94 year old woman who made significant improvements using Orthromolecular nutrition. www.georgebatista.com

We are giving you a fresh take on celebrity health news and medical news that you can't get anywhere else! We're talking about Al B. Sure!'s wild survival story (coma, liver transplant, and those Diddy rumors), plus Nate Robinson's journey from NBA All-Star to kidney transplant survivor.I misspoke on the LIVE today. I said that it is standard of care for one to be referred to a nephrologist when the eGFR is less than 30. I meant to say that it is standard of care to refer a patient to a nephrologist when the eGFR is less than 60 and when the patient is in stage 3 CKD.This podcast is intended to be informational only.  It is not a medical consultation, nor is it personalized medical advice.  For medical advice, please consult your physician.Did you hear about Fox News commentator Camryn Kinsey fainting on live TV? Let's talk about why fainting happens—and why it's not just about “catching your breath.” Also, have you heard about That's So Raven, Disney Star, Rondell Sheridan's pancreatitis battle? It's a wake-up call for sure, and we'll talk about what you need to know plus so much more!#HealthHappyLifePodcast #DrFrita #MedicalMondays #MedicineInTheNewsHere are a few helpful resources to help on your journey to wellness:▶️ Subscribe so you will never miss a YouTube video.

The authors evaluate the efficacy and safety of emerging therapeutic strategies for CKD management, including sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), finerenone, sacubitril/valsartan, and potassium binders. Read the full text manuscript at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.70014.

In this podcast, Dr. Valentin Fuster reviews findings from the SUMMIT trial, which examined how tirzepatide impacts patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD). The study revealed that while tirzepatide improved cardiovascular outcomes and slightly boosted kidney function, the benefits in CKD patients may stem from mechanisms beyond glomerular filtration alone.

During this episode a panel of experts discuss the patient journey through the interpretation and application of safety and efficacy data to establish and maintain protocols designed to address optimal VTE treatment pathways. Claim CE and MOC Credit at bit.ly/VTEPJ6 

In this episode, Lori talks with nephrologist Dr. Arun Malhotra about what inspired him to pursue nephrology and dives into an important discussion about the connection between chronic kidney disease (CKD) and high potassium, also known as hyperkalemia. They cover symptoms to watch for, the role of diet, how to manage potassium levels, and the importance of working closely with healthcare providers.

The interplay between cardiovascular disease, chronic kidney disease (CKD), and diabetes is complex and often underappreciated.   Credit available for this activity expires: 4/30/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002395?ecd=bdc_podcast_libsyn_mscpedu

In this episode, we explore how data analytics and clinical expertise can transform kidney health management for health plans. Joining the conversation is Joe Vattamattam, Founder and President of Healthmap Solutions, who shares insights on why tackling chronic kidney disease (CKD) and end-stage renal disease (ESRD) is crucial. Tune in to learn how Healthmap leverages technology, clinical support, and innovative strategies to improve outcomes for patients and providers.This episode is sponsored by Healthmap Solutions.

In this powerful episode of Diary of a Kidney Warrior Podcast, host Dee Moore is joined by Nick Palmer, who shares his extraordinary journey of living with chronic kidney disease (CKD) and focal segmental glomerulosclerosis (FSGS). Diagnosed at just 19 years old, Nick opens up about navigating the complex realities of kidney disease as a young adult—balancing university, a demanding career, and the emotional toll of a condition that would require multiple transplants and ongoing dialysis.   With unflinching honesty, Nick reflects on his decision to decline a third kidney transplant and instead embrace home nocturnal dialysis—a choice that profoundly improved his quality of life, restored his sense of independence, and helped him reclaim control of his health. He discusses the impact of this decision on his mental well-being, family life, and career, and how it ultimately allowed him to thrive in ways he never expected.   Nick's story challenges traditional narratives around kidney treatment, shining a light on the importance of patient choice, education, and mental health advocacy in chronic illness care. This episode is a must-listen for anyone navigating kidney disease, healthcare professionals, or anyone seeking inspiration from a story of resilience and informed self-advocacy.   Key topics include: Living with FSGS and the impact of early diagnosis The emotional and physical toll of dialysis in early adulthood The recurrence of FSGS post-transplant Choosing nocturnal dialysis and the profound benefits for quality of life Mental health, self-advocacy, and redefining what it means to live fully with CKD   Follow Diary of a Kidney Warrior:  

About 40% of people with diabetes will develop chronic kidney disease (CKD), making diabetes the leading cause of CKD. Mortality in people with both diabetes and CKD is higher than in those with either condition alone.In this episode of the Clinical Update podcast, the MIMS Learning editors look at diabetes-related kidney disease. They discuss the mortality and morbidity associated with the condition, its diagnosis and its management — including the role of SGLT2 inhibitors.The editors also review what NICE says about glycaemic and lipid targets in this population, noting that glycaemic targets become less strict as CKD progresses.You can access the website version of this podcast on MIMS Learning to make notes for your appraisal. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser.Please note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.Further learning on MIMS LearningAddressing polypharmacy in cardio-renal-metabolic diseaseDiabetes-related kidney disease: prevalence, diagnosis, and impactDiabetes-related kidney disease: five steps to optimise managementDiabetes-related kidney disease: therapy optionsGuidance update: latest NICE guidelines on cardiovascular disease risk assessment and reductionGuidance update: NICE guidelines on chronic kidney diseaseMIMS resourcesSGLT2 inhibitors for the treatment of type II diabetesGLP-1 agonists and GIP/GLP-1 agonists for the treatment of type II diabetes Hosted on Acast. See acast.com/privacy for more information.

In this feature segment of asPERusual, guest listener and patient partner Kathy Smith offers a short recap and her key takeaways from last week's episode of asPERusual focused on patient engagement within the Can-SOLVE CKD Network -- a Canada-wide network of patients, scientists, and health care professionals devoted to creating innovative kidney care solutions. Tune in to this short (~10 minute) episode, regardless of whether you want to compare reflections or get the Coles notes of the full Can-SOLVE CKD Network episode.Episode Transcript:Anna:Hi everyone! Welcome to onePERspective - a bi-weekly segment in which patient partner Kathy Smith shares a synopsis and key reflections from the previous episode of asPERusual -- a podcast for practical patient engagement. My name is Anna Chudyk and I am asPERusual's host. In today's episode, Kathy will be commenting on S3E2 of asPERusual. In that episode, I sat down with Melanie Talson and Cathy Woods to learn all about patient engagement within the Can-SOLVE CKD Network, which is a Canada-wide network of patients, scientists, and health care professionals devoted to creating innovative kidney care solutions. Alright Kathy, lets turn it over to you and your onePERspective. Kathy Smith:Thank you, Anna and hello, everyone. I am speaking to you from the centre of Canada along the shores of Lake Superior, or Gitchigumi, the largest, deepest, coldest and cleanest freshwater lake in the world. I wish to acknowledge that my City of Thunder Bay is situated on the traditional land of the Anishinaabe peoples, including the Ojibwa of Fort William First Nation, signatories to the Robinson Superior Treaty of 1850. I thank our ancestral land keepers for centuries of sustainable stewardship of this beautiful area and for kindly sharing the bounties of this rich land with everyone. I also wish to express my appreciation for the significant contribution of the Metis nation. I am sorry for the mistakes made and mistreatment of Indigenous peoples by colonists in the past and I am committed to working together for truth and reconciliation. Miigwetch.If ever there was an award for a solid and sustainable engagement strategy, today's Chronic Kidney Disease (CKD) Px engagement platform would certainly be a strong contender. I am most impressed with how they have integrated the Indigenous voice and with their capacity-building training modules, including bi-directional Capacity Bridging.Melanie Talson & Cathy Woods from Can-SOLVE CKD: Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease describe their network as a national partnership of lived experience patients; learned experience researchers; laboured experience health care workers and clinicians; and leaders – the managers and policy makers. The four “Ls” work together to transform treatment and care and improve the outcome for those living with debilitating chronic kidney disease.Can-SOLVE's tagline is “the right treatment for the right person at the right time and place.” No small task when you consider CKD affects a disproportionate number of Indigenous people many of whom live in remote, even fly-in, communities. That is why I am so impressed to see that this group has a strategy for addressing that barrier to care. Can-SOLVE has an Indigenous-led partner group, IPERC -Indigenous Peoples Engagement and Research Council. IPERC's focus is on Indigenous kidney care challenges unique to this harder to reach, often underserved, group. Cathy, of the Bear Clan, is a member of Naicatchewenin First Nation in Northwestern Ontario, is the patient partner and a lead researcher of the Kidney Check Research Project which seeks to screen, triage and treat Indigenous people living in rural and remote communities in the three western provinces and British Columbia. Patient partners within both groups prioritize and co-lead research projects like this one, ensuring meaningful and relevant engagement at every stage. Furthermore, there is a Patient Governance Council – a leadership team made up of representatives of both interest groups who decide on plans and policies that affect the entire CKD community.Our speakers have done a great job describing each of the 6 Rs upon which they built their engagement platform: Respect, Responsibility, Reciprocity, Relevance, Relationships and Realness. Realness is a term I had not heard of in engagement platforms before. But I do understand and appreciate its inclusion. We need to fit our hats to the task as I like to call it. Our real life has given each of us many hats, but which shall we wear to best meet the asks of the task? Patients and providers work best when they find common ground, common interests and common language with lived experience input “as is”. Bring your real, authentic self to the table. Respect for individual differences and perspectives sees real-world impacts.Equally impactful is how patient partners like Cathy describes her involvement in CANSOLVE as healing, empowering, and deeply purposeful – creating a space for ordinary people to accomplish extraordinary things. As the famous anthropologist, Margaret Mead, phrased it; never doubt that a small group of thoughtful, committed citizens can change the world. It's the only thing that ever has.”Finally, I'd like to acknowledge CANSOLVE's Bridging Capacity. Building capacity is an integral component of patient engagement strategies. Training modules are co-designed to buildup the knowledge and provide the necessary tools for patients to engage in a research project. These helps are unidirectional in scope. So how does Bridging Capacity differ from Building Capacity? Bridging Capacity is bi-directional. Patients and providers both learn from each other. I cant think of a better tool for bridging the power differential and creating strong work relationships!All in all, CANSOLVE and IPERC have really empowered patients to enhance research relevance to better the outcome for all with chronic kidney disease.PERsonally SpeakingMy three take-aways:Could this Indigenous Partnership (IPERC) model be used to incorporate the voice of many other underserved populations – the remote; the homeless; the new Canadians? These groups are surely concerned about their health, but they do not want to, or cannot, come to our Table. So, meet them where they are at with separate interest groups run by their own leaders and their own peers. Then the leaders of the various interest groups could come together to form an overarching Senior Team. This makes for a much more inclusive and diverse Patient Engagement Platform!Capacity Bridging This was a term I had not heard of before but I very much like it for the added emphasis it brings to an engagement platform. This bridging is a bi-directional sharing of knowledge between the lived experience experts and the learned experience experts. It stresses the importance of respecting that all members of the team bring unique experiences and skill sets. This concept guides mentorship, training, and peer review practices across the network. Patient partners are highly valued for their different hats they bring to a task on the TEAM: Together Everyone Accomplishes More. Together is better!Relationship Building is at the heart and soul of every Patient Engagement Platform. It takes a patience of time and a whole lot of money. It must be accounted for in research budgets and run by a paid, highly trained and skilled multi-tasker manager. Anything less jeopardizes the success of the engagement platform and perhaps the relevance and value of the research itself.At this time, I would like to thank everyone for the privilege and the opportunity of speaking to you on these podcasts. In particular, I want to do a huge shout out to my heroine, Anna, for including me and asking me to do these podcasts. As Anna is moving forward with the pediatric and youth groups, I want a fresh voice to help her with these podcasts. But in any case, I wish Anna all the best as she goes forward with this labor of love. I can't tell you how much time and effort Anna has shown and the passion that she has dedicated to helping all patients engage meaningfully and relevantly with academic partners in research. Thank you. And happy trails, Anna. Anna:Thanks Kathy for this, and all of the other onePERspective's to date. As you know, your encouraging emails summarizing all you learned from the release of this podcast's initial episodes were the impetus for creating the onePERspective segment. I've really enjoyed hearing your reflections and collaborating with you on the creation of these episodes. Even with all your engagement related jet setting, I could also count on you to come through on your episode… and somehow find the time for it. Big hugs to you and I'm glad we have research we're collaborating on together so it's not actually a good bye. Moving forward this season, I'm going to continue with onePERspective but it's taking a different twist. A big reason why I have chosen to focus the remainder of season 3's episodes on engaging children, youth, and families is for my own learning as I expand my research program to focus on these populations. I am currently moving in this direction through a pharmacogenetics study I am collaborating on with my colleague Abdullah Maruf, as well as work I am doing with colleagues to redesign pediatric-to-adult transition care services for youth and families living with congenital heart disease. Sasha Kullman is a talented PhD trainee working under my supervision on the congenital heart disease project. Given her passion and penchant for patient engagement and knowledge translation, I thought that it would be a great opportunity for her to take over onePERspective this season, and offer a trainee perspective on her take-aways from the episodes. She's very brilliant and I can't wait to hear her episode takeaways as her insights always make me think.In the next full episode of asPERusual, I kick off the rest of this season's focus on how to meaningfully engage children, youth, and families in health research. Guests Brianna Hunt, Onalee Garcia-Alecio, and Michelle Roy, will share their experience with engaging in the iCARE study—Canada's largest cohort of youth with type 2 diabetes. We'll also discuss what makes engagement meaningful over time, the value of lived experience, and practical tips for involving youth and families in ways that are inclusive, trauma-informed, and fun. The episode is going to drop on April 28th so be sure to check it out by visiting our website asperusual.substack.com or wherever it is that you download your other podcast episodes from. If you do visit the website, be sure to check out the interactive transcript from this, and other episodes, as well as to subscribe to the podcast's newsletter! As always, you can reach me by emailing anna.asperusual@gmail.com or by adding me to LinkedIn by searching Anna M. Chudyk – CHUDYK.Until next time, thanks again for tuning in and let's keep working together to make patient engagement the standard, or asPERusual. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit asperusual.substack.com

From 2013 .... Lori Hartwell discusses her book "Chronically Happy: Joyful Living in Spite of Chronic Living." Hartwell has lived for most of her life with chronic kidney disease. She is the founder and president of the Renal Support Network .... and co-host of "KidneyTalk," a biweekly webcast centered on issues related to CKD.

Video Version Only on HCPLive! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explored two key trial updates in type 2 diabetes (T2D) care at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions. SOUL Trial SOUL, a double-blind, placebo-controlled, event-driven trial, was designed to assess the cardiovascular effects of oral semaglutide (Rybelsus) in patients with T2D and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). A total of 9650 patients aged ≥50 years were enrolled across 450 centers in 44 countries. Analyses showed oral semaglutide (Rybelsus) was linked to a 14% reduction in major adverse cardiovascular events (MACE) in high-risk patients with T2D. This reduction included the incidence of cardiovascular (CV) death, myocardial infarction (MI), or stroke compared to placebo (HR, 0.86; 95% CI, 0.77 to 0.96; P = .006) over a median follow-up of 47.5 months. A 26% reduction in non-fatal MI was the primary driver of benefit, while safety findings identified gastrointestinal adverse events as more common with oral semaglutide. Based on these results, Novo Nordisk announced plans to pursue regulatory approval for a label expansion of oral semaglutide to include MACE risk reduction in adults with T2D and established CV disease. STRIDE Trial STRIDE, a double-blind, randomized, placebo-controlled trial initiated in 2020, assessed the effects of semaglutide 1.0 mg (Ozempic) on functional outcomes, including walking distance, in patients with T2D and peripheral artery disease (PAD). Conducted across 112 sites in 20 countries, the trial randomized 792 patients to receive semaglutide or placebo for 52 weeks. Analyses showed semaglutide use was associated with improvements in maximal walking distance, quality of life, and ankle-brachial index (ABI). SOUL met its primary endpoint, with semaglutide favoring the ratio from baseline in maximum walking distance at 52 weeks (1.21 [interquartile range, 0.95–1.55] vs 1.08 [0.86–1.36]), with an estimated treatment ratio (ETR) of 1.13 (95% CI, 1.06–1.21; P = .0004). At week 57, the improvement in walking distance was higher with semaglutide (ETR, 1.08; P = .038). Quality-of-life scores (VascuQoL-6) at week 52 were significantly higher in the semaglutide group (median difference, 1.00; P = .011), as were improvements in pain-free walking distance (ETR, 1.11; P = .0046). Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Editor's Note: In this episode, there was an error in the discussion about the new dosing for Rybelsus in the SOUL trial. The corrected information is that the 14 mg dose is now 9 mg with the new formulation, due to improved absorption. The full corrected statement is: “Instead of 3 mg, the new dose is 1.5 mg; instead of 7 mg, it's 4 mg; and instead of 14 mg, it's 9 mg.”

Let's talk real about kidney-friendly diets—without the fear-mongering. In this episode, Dr. Marianne welcomes Vanessa Connelly, RD (@grainandgreen.kidneys), for a candid conversation about what it actually means to eat in a kidney-supportive way—without triggering disordered eating patterns. Vanessa shares how she helps folks navigate complex medical nutrition guidance with compassion, nuance, and zero shame. Whether you're living with chronic kidney disease, supporting a loved one, or just curious about how diet culture shows up in medical spaces, this episode is a must-listen. ABOUT VANESSA CONNELLY, RD Vanessa is a registered dietitian nutritionist and board certified kidney nutrition specialist with over 20 years experience working with folks who have chronic kidney disease. She is a South Carolina living Maryland native who has helped hundreds of clients with CKD slow down or prevent dialysis without giving up their favorite foods. Her passion is to help people understand how eating the right foods can truly help preserve and protect kidney function. She's about ditching the stress and helping you thrive with CKD one bite at a time. Vanessa graduated from the University of Maryland at College Park and attended the Medical University of South Carolina to complete the requirements of the Dietetic Internship. When not working you can find Vanessa busy living life with her husband and two kiddos, listening to true crime podcasts or enjoying a workout. CONTACT VANESSA IG: @grainandgreen.kidneys TikTok: @grainandgreen.kidneys Website: www.grainsandgreenkidneys.com Email: vanessa@grainsandgreenkidneys.com CHECK OUT MORE EPISODES ON HEALTH & NUTRITION:   > Diabetes, Accessibility, and Eating Disorders on Apple or Spotify. > Ableism & Common Myths About Diabetes on Apple or Spotify.   INTERESTED IN HANGING OUT MORE IN DR. MARIANNE-LAND? Follow me on Instagram @drmariannemiller Join my $99/month Dr. Marianne-Land's Binge Eating Recovery Membership Program Live in the UK, US, or Canada? Sign up for 1:1 binge eating recovery coaching via my Elite Binge Eating Recovery Method  Live in California, Texas, or Washington, D.C. and interested in eating disorder therapy with me? Sign up for a free, individual 15-minute phone consultation via my website, and I'll get you to where you need to be! Check out my blog. Want more information? Email me at hello@mariannemiller.com

In this episode, a panel of experts discuss existing and emerging VTE (venous thromboembolism) treatment options for the complex patient, such as a patient who has been diagnosed with cancer, end stage renal disease (ESRD), chronic kidney disease (CKD), or is obese.  Claim CE and MOC Credit at https://bit.ly/VTEHBCPX

In this deeply moving episode of Diary of a Kidney Warrior Podcast, host Dee sits down with the incredible Rachel, a true example of strength and resilience in the face of Chronic Kidney Disease (CKD). Diagnosed as a child, Rachel's story spans decades — from routine check-ups in her youth to navigating the complexities of motherhood with CKD, dialysis, and ultimately receiving a life-saving kidney transplant from her mother.   With warmth and honesty, Rachel reflects on the early signs of CKD, the emotional and physical challenges of pregnancy with kidney disease, and the toll dialysis took on her young family. Through it all, her determination to stay strong for her children and her unshakeable hope carried her forward.   This episode is not just about survival — it's about the importance of support, the power of informed choices, and the life-changing gift of organ donation. Rachel's story will leave you inspired and uplifted.   Whether you're a patient, carer, or healthcare professional, this conversation offers vital insights, encouragement, and a powerful message of perseverance and gratitude.   Follow Diary of a Kidney Warrior:  

In this podcast recorded in early March, David Phizackerley (DTB Editor-in-Chief) and James Cave (DTB Editor-in-Chief Emeritus) provide an overview of the April 2025 issue of DTB. The editorial discusses concerns over the use of feminist empowerment messages to sell tests and treatments. A DTB Select item summarises the results of an observational study that assessed the association between initiation of a triptan and the risk of myocardial infarction or stroke. The main article provides an overview of initiating angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists in adults with CKD, highlighting current guideline recommendations and providing a practical approach to dealing with the challenges associated with their use.   Links Health Innovation Network: https://thehealthinnovationnetwork.co.uk/news/launch-of-new-game-changing-guide-to-tackle-overprescribing-and-support-governments-shifts-to-prevention-and-community/    Tackling overprescribing report: https://thehealthinnovationnetwork.co.uk//wp-content/uploads/2025/02/Health-Innovation-Network-Polypharmacy-Guide-Feb-2025.pdf    GP Evidence: (https://gpevidence.org/)   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

Did you know that patient registries play a vital role in improving kidney disease treatment and outcomes? In this episode, we're diving into the KidneyCARE Study—a patient registry that uses real-world data to better care for people with kidney disease. We sat down with experts as they explained what a patient registry is and why people with kidney disease may want to join the KidneyCARE Study. In today's episode we heard from:    Kerry K. Willis PhD- Dr Willis is the Chief Scientific Officer of the National Kidney Foundation (NKF). Since joining NKF in 1998, her major focus has been on the analysis and application of clinical evidence to improve care and outcomes for people living with kidney disease. She oversees all NKF-sponsored research and professional education programs, including the Spring Clinical Meetings; population health programs that facilitate health system and practice engagement around CKD as a quality improvement target; the Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines; KDOQI quality measurement initiative; and four peer-reviewed journals devoted to chronic kidney disease. She led the development of and currently manages the Kidney CARE (Community Access to Research Equity) Study, the first national CKD patient registry to combine patient-reported data with clinical data from electronic health records.     Rachel Claudin, BS, CCLS- Rachel Claudin is the Patient-Centered Research Director at the National Kidney Foundation (NKF). Her main work for the past three years has been focused on the advancement of the KidneyCARE Study. As a person living with Lupus Nephritis, she is excited for the patient-entered data collected by the Study to increase and improve kidney care research. Previous to the NKF, Rachel worked in hospital and hospice settings advocating for patients utilizing the shared decision-making model of healthcare. Cari Maxwell- Cari has lived with Polycystic Kidney Disease (ADPKD) since 1989, and her personal experience, along with the experiences of her father and two siblings, fuels her advocacy for advancements in PKD treatment. She participated in the Tolvaptan Reprise trial, which led to the first-ever FDA-approved treatment for ADPKD—a treatment she continues to benefit from today. As a member of the NKF Kidney Advocacy Committee, Cari is passionate about promoting patient education, early detection, and scientific progress through patient-centered clinical research. She is dedicated to ensuring that others have access to life-changing treatments and are empowered to advocate for their health through proactive care. Cari currently works in health care cost containment strategies, where she applies her expertise to enhance patient access and outcomes. Sandy Gilbert PhD- Sandy Gilbert is the Senior Director of Patient Outcomes Research at the National Kidney Foundation (NKF), where she manages the KidneyCARE (Community Access to Research Equity)™ Study. Since joining NKF in 2024, her focus has been on developing and overseeing this pioneering national kidney disease patient registry, the first to integrate patient-reported data with clinical data from electronic health records. The goal of the Registry is to generate critical insights into disease progression, treatment outcomes, and health disparities, in support of NKF's mission to improve kidney health and drive innovation in kidney research and healthcare. Sandy works closely with teams of researchers and health system partners to expand the study's reach and ensure that it reflects the needs of diverse patient populations, including those from underserved communities. Additional Resources: KidneyCare Study Information Contact Information: Call: 212.889.2210 ext.134 M-F 10am-4pm CT  Email: kidneycarestudy@kidney.org   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

In this powerful and informative episode of Diary of a Kidney Warrior Podcast, Dee is joined once again by the brilliant Professor Ibi for the third time—this time to dive deep into the essential topic of haemodialysis. Whether you're newly diagnosed, a long-term dialysis patient, or supporting a loved one with chronic kidney disease, this episode offers clear, compassionate insights to help you navigate the dialysis journey.   Together, they unpack the basics of how haemodialysis works, including vital topics like fluid management, the importance of dry weight, blood pressure monitoring, pump speeds, and the common causes of cramps during treatment. Professor Ibi explains why dialysis sessions are structured the way they are and what happens when treatments are missed or cut short. You'll also hear practical tips on managing the physical impact of dialysis, dietary considerations, and the realities—both good and challenging—of life on haemodialysis.   This episode is a must-listen for anyone impacted by CKD, offering clarity, empowerment, and encouragement to keep going strong.     Follow Diary of a Kidney Warrior:  

Tune in to The Heart of Innovation this week as we share an incredible story of a young woman who helped save her grandfather's life and now is trying to save others through organ donation advocacy. Since it's National Kidney Month, Emmy Award-winning journalist Kym McNicholas and Dr. John Phillips interview Danica Almazan, RN and Miss Marin County 2025, whose family's courageous fight against kidney disease sparked a powerful mission of hope. You might wonder why we are talking about kidney disease on a show about cardiovascular and vascular health. Kidney disease, especially in advanced stages can lead to peripheral artery disease, which is poor circulation in mainly the legs, and lead to amputation. Many of the peripheral artery disease (PAD) patients both Kym and Dr. John support have CKD and ESRD, some of which are also in need of a kidney transplant. They want to get the word out there on the importance of kidney health as well as raise awareness that all kidney disease patients should be checked for peripheral artery disease and to find a doctor who specializes in opening the small vessels below the knee and into the foot, which is where kidney disease patients are typically stricken with PAD. Whether you're impacted by peripheral artery disease, kidney health challenges, or simply want to understand the power of family support, this episode is a must-watch! #KidneyHealth #OrganDonation #TheHeartOfInnovation #NationalKidneyMonth #MissMarin2025 #peripheralarterydisease #padsupport #CLI #criticallimbischemia

Why does a potentially deadly condition that affects 1 in 7 adults fly under the radar, undetected and undiscussed? Join us on this episode of Quality Matters as we explore Chronic Kidney Disease (CKD), a silent killer that's finally coming into the limelight of quality improvement.Our conversation begins with Dr. Ben Oldfield, a primary care physician, who sheds light on the startling prevalence and hidden complexities of CKD. Why is it so hard to detect, even with simple blood and urine tests? And why does this condition, despite its extensive impact, often get lost in the shuffle of busy health care visits?We'll unpack the challenges of diagnosing and managing CKD, exploring the emotional weight the diagnosis carries for patients and the hurdles clinicians face in communicating about it. Discover why CKD is a “loaded term” and how we can shift the narrative from fear to empowerment.But that's not all. We'll also tackle the big picture: How CKD fits into the broader landscape of cardiovascular, kidney, and metabolic (CKM) disorders. Could a holistic approach to these interconnected conditions revolutionize patient care?The conversation ends with Ben's thoughtful observations on how classic literature, particularly epic poetry, helps doctors make sense of health care's emotional complexities, connect with patients and find empowerment in the face of life and death.Join us as we explore how we can move CKD from the sidelines to the front lines of quality improvement, and how collaborative, longitudinal care can make a real difference.Key Quote:“Thinking about chronic kidney disease is a longitudinal process. It's only half the story to make the diagnosis in a snapshot in time. What's the follow up like? How are we doing with the patient over time? Because oftentimes quality measures can look at things in a snapshot in time. Chronic kidney disease really begs us to think more longitudinally.”“Benjamin Oldfield, MDTime Stamps:(02:54) The Silent Nature of CKD(07:05) Quality Measurement and CKD(11:08) The Link Between CKD and Cardiovascular Kidney Metabolic syndrome(13:06) CKD and CKM as Quality Priorities (15:45) Narrative Medicine and Personal InsightsLinks:NCQA Kidney Health ToolkitConnect with Benjamin Oldfield

The Clare branch of the Irish Kidney Assocation says it's "lobbying very hard" for a dialysis unit in Clare this World Kidney Day. In conjunction with the annual awareness day which has rolled around again, the Irish Kidney Association, or IKA, has launched its '1 in 10 People' campaign to shine a light on kidney health awareness. The campaign, according to the IKA, is intended to make people more aware of kidney-related health conditions. It's estimated that one in 10 people in Ireland and one in seven over the age of 50 are living with Chronic Kidney Disease or CKD. Of these, a startling 98% don't know they have the condition which is on track to be the fifth leading cause of death here by 2040. Clare people in need of renal care currently have to go either to University Hospital Limerick or its satellite centre on the Dock Road in Limerick. While the HSE had at one point said Ennis Hospital would have a dialysis unit by the end of this year, this has now been pushed back to November 2026. Chairperson of the Clare branch of the IKA Dermot Hayes people here are travelling an exceptional distance to access the care they need. At this week's meeting of Clare County Council, Clarecastle Sinn Féín Councillor Tommy Guilfoyle tabled a motion seeking clarity on the delivery of the Ennis dialysis unit. Specifically, he's requested a precise timeline on the commencement of services, confirmation of its location, details of the contractor and confirmation of the project's current status. He says many in this county are confused and need answers as a matter of urgency.

Last year, 9,000 deceased donor kidneys were discarded due to storage and time limitations. A kidney “life support” machine could change that. Also, the SS United States will join Florida's 4,300 artificial reefs—human-made places for fish and other marine life to live. How do these reefs work?The Effort To Save Thousands Of Donor Kidneys From Being WastedSylvia Miles was diagnosed with lupus in 2006, a chronic autoimmune disease that causes the body's immune system to attack healthy tissue—including her kidneys.Miles, who lives in Indianapolis, was later diagnosed with advanced kidney disease, and was in need of a kidney transplant.Kidney diseases are one of the leading causes of death in the United States with 37 million people living with chronic kidney disease. Together with advanced kidney disease—the later stage of CKD—it cost Medicare billions of dollars in recent years.People like Miles, who need a kidney transplant, wait an average of five years—often on dialysis.But despite the long waitlists and organ shortages, around 9,000 kidneys from deceased donors last year were discarded due to perceived issues with their viability. A new Indiana-based organization, 34 Lives, is working to limit that waste and rehabilitate the organs.Read the rest of this article on sciencefriday.com.Ocean Liner SS United States Will Become An Artificial ReefThis week, after a notable career, the SS United States, a 1950s ocean liner, took her sunset cruise. Like many retirees, the ship is heading south—from Philadelphia to Florida—where she'll be reinventing herself. In this next chapter, the SS United States will have new passengers: fish and other marine creatures. The ship will be sunk to the bottom of the sea and turned into an artificial reef, joining more than 4,300 artificial reefs off the coast of Florida.Other sunken ships have become artificial reefs in the past, which have helped boost marine life as well as scuba diving and fishing tourism. Host Flora Lichtman speaks with Scott Jackson, a regional specialized agent with the Florida Sea Grant and University of Florida IFAS extension, about the science behind artificial reefs, and what has been learned from decades of research.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Welcome to another episode of Discovering Nutrition with Cronometer! In this episode, our host Eliisa sits down with Jen Hernandez, a registered dietitian and founder of Plant-Powered Kidneys, to explore an often-overlooked topic—kidney health. Chronic kidney disease (CKD) affects millions worldwide, yet many people don't realize they have it until their kidney function is significantly impaired. Jen shares her expertise on how nutrition plays a vital role in kidney function, debunks common renal diet myths, and explains why tracking key nutrients can help prevent and manage CKD. Learn how small, intentional changes—like adjusting protein intake and increasing plant-based foods—can make a big impact on long-term kidney health. Key Notes: • Understanding CKD: Why kidney disease is often called the “silent killer” and how it affects overall health. • Top Risk Factors: The role of high blood pressure, diabetes, and diet in kidney disease progression. • The Changing Renal Diet: Debunking outdated advice on potassium and protein intake. • Tracking Kidney Health: How tools like Cronometer's PRAL score help monitor diet acidity and kidney function. • Small but Powerful Changes: Simple diet swaps to reduce strain on the kidneys. • Hydration & Kidney Function: The importance of tracking fluid intake and choosing the right beverages. • Actionable Takeaway: Add one plant-based protein swap to your meals to support kidney health.   www.instagram.com/plantpoweredkidneys https://www.plantpoweredkidneys.com/ https://www.facebook.com/plantpoweredkidneys/ www.cronometer.com

In this special collaboration with NephMadness, we're diving into the world of nephrotoxins with an expert panel from Virginia Commonwealth University. NephMadness is an educational competition modeled after March Madness, and this year, one of the featured regions focuses on plant-based nephrotoxins. Together, with our expert panel we break down the competing nephrotoxin teams: Tubular Toxins vs. Oxalate Offenders. Joining us are Dr. Anna Vinnokova (Nephrologist), Dr. Rachel Khan PharmD (Neph pharmacist), Dr. Ethan Downes (Nephrology fellow), and the legendary nephrotoxicologist, Dr. Josh King (Board certified Nephrologist and Toxicologist). We ALMOST named this episode "Getting Downe with the Mad Neph King and the Bean Queens"... but we didn't, your welcome. After the show, go to the blog and vote for your favorite!Expect irreverent musings, deep dives into toxic plant exposures, and a mystery case reveal that will leave you questioning your diet.Topics and Timeline of Episode:IntroListener Guesses With Josh and Ryan– 8:30Listener Winner – 25:42NephMadness and Guest Introductions – 28:07Toxin Reveal – 33:41NEJM Case reportTubular Toxins – 35:46Aristolochic Acid & the Belgian Weight-Loss Clinic Outbreak – 40:30Black Licorice & Its Surprising Toxic Effects – 47:16The Oxalate Offenders Team: How Dietary Oxalates Harm the Kidneys – 52:00Historical Context: First recognized through sheep die-offs when herds grazed on Halogeton glomeratus, a high-oxalate plant, leading to fatal poisoning.Oxalate in Plants: Functions to bind excess calcium in the soil.Impact on the Body: Plants high in oxalate but low in calcium can contribute to oxalate accumulation, this leads to binding calcium in the blood, creating calcium oxalate crystals and acute renal calculi. Chronic inflammation from excess oxalate deposition leads to CKD progression.High-Oxalate Foods: Spinach, Swiss chard, rhubarb, cashews. Everything in moderation!Practical Advice for Clinicians & Patients on Herbal Medicine Use – 1:00:00Resources for identifying nephrotoxic herbal productsTalk to your patients non judgmentally, open conversations, discuss efficacy (or lack there of, see resources below) and safetyHerbal medicines are not FDA approved and may not contain what they claim toHerbals may not all be safe: Josh King Discovering Contaminants– 1:01:11Wrap up– 1:08Key Takeaways:Aristolochic acid is a direct nephrotoxin, associated with progressive kidney damage and urothelial cancers.Black licorice toxicity results from...

The FiltrateJoel TopfSwapnil HiremathAC GomezSopia AmbrusoNayan AroraSpecial Guests Michelle Rheault, Director, Division of Pediatric Nephrology, Professor of MedicineTiffany Caza, Nephropathologist, Scientist and self-described Freely Filtered fan girlEditing bySimon Topf and Sophia AmbrusoShow Notes10. Healthcare Cyberattacks9. ApoE in C3 glomerulonephropathy8. Workforce woes in Adult and Pediatric Nephrology7. Hyponatremia correction meta-analysis6. Microvascular inflammation increases risk of graft loss - in all of its forms5. Xenotransplantation4. KDIGO CKD Guidelines3. Hypertension control trials (ESPRIT, BPROAD)2. The Renaissance of IgAN: IgAN treatment trials1. FLOW: GLP-1 RAs in CKD

Welcome to another episode of Discovering Nutrition with Cronometer! In this episode, our host Eliisa sits down with Jen Hernandez, a registered dietitian and founder of Plant-Powered Kidneys, to explore an often-overlooked topic—kidney health. Chronic kidney disease (CKD) affects millions worldwide, yet many people don't realize they have it until their kidney function is significantly impaired. Jen shares her expertise on how nutrition plays a vital role in kidney function, debunks common renal diet myths, and explains why tracking key nutrients can help prevent and manage CKD. Learn how small, intentional changes—like adjusting protein intake and increasing plant-based foods—can make a big impact on long-term kidney health. Key Notes: Understanding CKD: Why kidney disease is often called the “silent killer” and how it affects overall health. Top Risk Factors: The role of high blood pressure, diabetes, and diet in kidney disease progression. The Changing Renal Diet: Debunking outdated advice on potassium and protein intake. Tracking Kidney Health: How tools like Cronometer's PRAL score help monitor diet acidity and kidney function. Small but Powerful Changes: Simple diet swaps to reduce strain on the kidneys. Hydration & Kidney Function: The importance of tracking fluid intake and choosing the right beverages. Actionable Takeaway: Add one plant-based protein swap to your meals to support kidney health.   www.instagram.com/plantpoweredkidneys/ https://www.facebook.com/plantpoweredkidneys/ https://www.plantpoweredkidneys.com/blog/ www.cronometer.com

In this episode of the ASN Kidney Translation Podcast series, Dr. Matthew Sparks dives into groundbreaking kidney stone research from JASN, CJASN, and Kidney360, exploring CKD risk, asymptomatic stone passage, and how pharmacotherapy affects recurrence.

In this episode of the Diary of a Kidney Warrior Podcast, Host Dee sits down with Carl, a kidney transplant recipient whose journey began at just 15 years old. What started as flu-like symptoms soon revealed a rare virus that led to vasculitis, thrusting Carl into an unexpected battle with Chronic Kidney Disease (CKD).   Carl takes us through his diagnosis journey, navigating the shock of hospitalisations, intensive treatments—including chemotherapy—and the eventual need for dialysis and a kidney transplant. He opens up about the emotional toll of facing a life-changing condition as a teenager, the impact of medications like prednisolone, and how he found strength through each stage of his journey.   Despite the challenges, Carl's story is one of transformation. He reflects on his struggles with self-image, his gradual acceptance of CKD, and his decision to embrace life fully, even relocating to London post-transplant. For Carl, CKD isn't just a condition—it's a “superpower” that has shaped his resilience and outlook on life.   Beyond his own health journey, Carl shares his experiences as a father, balancing the demands of CKD with family life as he and his wife plan for a second child. He also provides an insightful comparison of renal care in Australia versus the UK, advocating for a stronger focus on preventative healthcare.   This episode is a powerful testament to the strength of the kidney warrior community. Whether you're a patient, a caregiver, or someone looking for inspiration, Carl's story is a reminder that with knowledge, support, and the right mindset, it's possible to thrive beyond kidney disease.   Follow Diary of a Kidney Warrior:  

In this special World Kidney Day podcast episode, Martina Pirotta, WKD Campaign Manager on behalf of the ISN, welcomes Dr. José Moura-Neto, President of the Brazilian Society of Nephrology, and Dr. Viviane Calice Silva, Director of the Department of Epidemiology and Prevention of Kidney Diseases at the Brazilian Society of Nephrology to describe the current landscape of chronic kidney disease (CKD) in Brazil. They discuss how Brazil commemorates World Kidney Day, with over 1,000 activities taking place annually, the impact of awareness initiatives, and a significant study on CKD screening using point-of-care creatinine testing across the country.

Ready to refine your approach to managing feline chronic kidney disease (CKD)? In this episode of Clinician's Brief Partner Podcast, Dr. Beth asks Dr. Stacie Summers, DVM, PhD, DACVIM, to share her expert insights into the often-overlooked role of uremic toxins in feline CKD. Listen in as they discuss why uremic toxins matter, their impact on the systemic health of CKD patients, and evidence-based strategies for effective management.Sponsored by DechraContact us:Podcast@briefmedia.comWhere to find us:Cliniciansbrief.com/podcastsFacebook.com/clinciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostTaylor Argo - Producer & Project Manager, Brief StudioRandall Stupka - Podcast Production & Sound Editing

In this essential follow-up episode, host Dee Moore welcomes back renal specialist dietitian Timi Omilana for the second part of their insightful series on food choices for kidney warriors. Whether you're managing chronic kidney disease (CKD), on dialysis, or supporting a loved one through their kidney health journey, this episode is packed with practical, evidence-based nutrition advice to help you make informed dietary choices.   This time, Dee and Timi focus on five key categories of foods that kidney patients should limit to better manage their health. From hidden sources of salt to unexpected risks in everyday drinks, they break down common food myths and provide realistic alternatives to support kidney function.   Key topics covered include: ✅ Salt and sodium intake – Why even ‘healthier' salt options might not be suitable and how to decode food labels to make better choices. ✅ Sugary and dark-coloured drinks – The truth about sodas, juices, and their impact on kidney health, plus kidney-friendly alternatives. ✅ Alcohol and kidney disease – How alcohol affects kidney function and what to consider if you choose to drink. ✅ Processed foods – Why pre-packaged and fast foods can be harmful and how to find convenient yet healthier alternatives. ✅ Fruits and vegetables to watch out for – Understanding potassium and phosphorus content in certain produce and how to balance your intake.   This conversation isn't about restriction—it's about empowerment. Timi provides practical tips and simple swaps that allow kidney warriors to enjoy food while protecting their health.  

BUFFALO, NY- January 28, 2025 – A new #research paper was #published in Volume 16, Issue 22 of Aging (Aging-US) on December 20, 2024, titled, “Impaired renal transporter gene expression and uremic toxin excretion as aging hallmarks in cats with naturally occurring chronic kidney disease.” This study, led by researchers Qinghong Li, James A. Holzwarth, Bethany Smith, Sonia Karaz, Mathieu Membrez, Vincenzo Sorrentino, Stacie Summers, Julie Spears, and Eugenia Migliavacca from Nestlé Purina Research and Oregon State University, explores how aging affects kidney function in cats with chronic kidney disease (CKD). The researchers found that older cats have lower levels of important kidney transporter genes, which usually help remove harmful waste products from the blood. These findings could help veterinarians better understand CKD in aging cats and offer insights that may be relevant to human kidney health. "Chronic kidney disease (CKD) is a naturally occurring kidney disease common in both geriatric cats and older people. Despite differing etiology, both species share many pathophysiological similarities, including chronic tubulointerstitial inflammation and fibrosis." Older cats with CKD struggle to filter toxins from their bloodstream effectively. In this study, the researchers analyzed kidney samples from two cat cohorts aged 6 to 21 years. The cohort number one included 41 colony cats: 28 control and 13 CKD cats. The cohort number two had 30 privately owned cats with 10 control and 20 CKD cats. They discovered that certain transporter genes, such as OAT1, OAT4, OATP4C1 and ABCC2, were significantly decreased in cats with CKD compared to healthy cats. The research team also found increased levels of harmful toxins in the blood of cats with CKD. Even healthy older cats had higher toxin levels compared to younger cats, showing that aging itself might contribute to declining kidney function. Monitoring kidney transporters levels and toxin buildup may help detect the disease early and improve treatment options. The researchers highlight the importance of regular veterinary check-ups to catch kidney problems early and keep cats healthier for longer. Because cats and humans share similar kidney health challenges, studying feline CKD can provide valuable insights into human kidney disease and aging. Continued research is essential to develop treatments that may improve kidney function in aging cats and potentially benefit humans as well. DOI - https://doi.org/10.18632/aging.206176 Corresponding author - Qinghong Li - qinghong.li@rd.nestle.com Video short - https://www.youtube.com/watch?v=WuEP9PXtx2A Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206176 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, trimethylamine N-oxide, indoxyl sulfate, OAT1, OATP4C1, ABCC2 About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Welcome to ohmTown. The Non Sequitur News Show is held live via Twitch and Youtube every day. We, Mayor Watt and the AI that runs ohmTown, cover a selection of aggregated news articles and discuss them briefly with a perspective merging business, technology, and society. You can visit https://www.youtube.com/ohmtown for the complete history since 2022.Articles Discussed (1/28/2025):Raising the Nerds Bar with Shaboozeyhttps://www.ohmtown.com/groups/mobble/f/d/nerds-super-bowl-ad-teaser-raises-the-bar-with-shaboozey/The Introverted Entrepreneurhttps://www.ohmtown.com/groups/hatchideas/f/d/the-challenges-youll-face-as-an-introverted-entrepreneur-and-5-key-strategies-to-help-you-overcome-them/Augmenting Humanityhttps://www.ohmtown.com/groups/nonsequiturnews/f/d/augmenting-humanity-exploring-the-essential-foundations-of-artificial-ultra-intelligence/1900 Year Old Papyrushttps://www.ohmtown.com/groups/mobble/f/d/1900-year-old-papyrus-reveals-gripping-case-about-roman-tax-fraud-and-forgery/Bookshop.org e-Book Storehttps://www.ohmtown.com/groups/mobble/f/d/bookshop-orgs-new-e-book-store-will-have-a-tough-time-taking-on-amazon/Crumb Trail to Recallhttps://www.ohmtown.com/groups/nonsequiturnews/f/d/bread-crumb-recall-sparks-nationwide-warning/Peel and Stick Radar Sensorshttps://www.ohmtown.com/groups/nonsequiturnews/f/d/logitechs-peel-and-stick-radar-sensors-could-let-companies-invisibly-monitor-their-offices/Limited Edition Asteroids Watchhttps://www.ohmtown.com/groups/nonsequiturnews/f/d/ataris-limited-edition-asteroids-watch-tells-time-with-orbiting-spaceships/Ooni Spiral Mixer will take your Wallet for a Spinhttps://www.ohmtown.com/groups/technologytoday/f/d/oonis-first-departure-from-pizza-ovens-is-a-799-spiral-mixer/FDA Approves Ozempic for CKD with Diabetes

In this enlightening episode of the “Diary of a Kidney Warrior” podcast, host Dee Moore engages in a comprehensive discussion with renal specialist dietitian Timi Omilana, marking the first installment of a two-part series dedicated to smart dietary choices for individuals managing chronic kidney disease (CKD). The conversation delves into kidney-friendly foods that not only support renal health but also enhance overall well-being.   Episode Highlights: • Embracing Plant-Based Proteins: Timi emphasizes the importance of incorporating plant-based proteins into the diet, highlighting their role in prolonging kidney function and delaying the progression to dialysis. Foods such as legumes, peas, and beans are particularly beneficial, offering advantages in managing diabetes and supporting cardiovascular health.  • Navigating Cultural Cuisines: The discussion acknowledges the significance of cultural diets and provides insights on making minor adjustments to enjoy traditional dishes without compromising kidney health. Resources from Kidney Care UK offer a variety of recipes tailored to diverse ethnic preferences, enabling CKD patients to savor familiar flavors responsibly. • Debunking Myths About Grains and Potatoes: Addressing common misconceptions, Timi provides practical cooking methods to safely include grains and potatoes in a CKD-friendly diet. The conversation also explores nutritious and convenient breakfast cereal options suitable for individuals with kidney concerns. • Smart Snacking Strategies: Concluding on an encouraging note, the episode reveals that snack foods can be part of a kidney-friendly diet. With thoughtful choices and healthy substitutions, those managing CKD can enjoy satisfying snacks without guilt.   Join Dee and Timi as they navigate essential dietary choices for kidney warriors, sharing expert advice and practical tips to inspire listeners on their journey toward better health. Stay tuned for the next episode, where they will discuss foods to limit, concluding this insightful series on dietary management for CKD.   For updates and more, follow Dee Moore on:   Instagram: www.instagram.com/diaryofakidneywarrior  Facebook: www.facebook.com/diaryofakidneywarrior  Twitter: www.twitter.com/diaryofakidneyw  Tik Tok: @diaryofakidneywarrior  Youtube: https://www.youtube.com/channel/UChGUfib7lu9eKENlLJ6lafw Linkedin: https://www.linkedin.com/in/dee-moore-diaryofakidneywarrior   Join the Diary of a Kidney Warrior Family Mailing list to get new episode reminders, episode links, Vlogs, newsletters and more: diaryofakidneywarrior.getform.com/rjv47   WhatsApp Follow the Diary of a Kidney Warrior Podcast (Kidney Health Podcast) channel on WhatsApp: https://whatsapp.com/channel/0029VaO3ms71iUxipp1eeh2r Follow Timi Omilana   Twitter: @timmieyRD LinkedIn: Timilehin Omilana   Kidney Care UK   Kidney Kitchen   https://www.kidneycareuk.org/about-kidney-health/living-kidney-disease/kidney-kitchen/   Website: www.kidneycarekuk.org Email: info@kidneycareuk.org Tel: 01420 541 424 Facebook: www.facebook.com/kidneycareuk.org Instagram: @kidneycareuk YouTube: https://www.youtube.com/channel/UCeqQTdAsEzXphqjHVtcTD-A   To sign up to receive the Kidney Matters Quarterly Magazine Email: info@kidneycareuk.org   Disclaimer: The views and opinions expressed by Guests on this podcast are those of the Guest and do not necessarily reflect the official policy or position of Dee Moore or Kidney Care UK. Any content provided by our Guests are of their opinion, and are not intended to malign any religion, ethnic group, club, organisation, company, individual or anyone or anything.   The information shared in this episode is for educational purposes only.    

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/using-newer-agents-in-chronic-hyperkalemia-management-9953SummaryIn this concise CME/CE podcast, a cardiologist and primary care physician review hyperkalemia management options that safely allow continuing GDMT for patients with heart failure or CKD. Using case examples, the clinicians provide education on individualizing treatment and addressing disparities in care.Learning ObjectiveAt the conclusion of this activity, participants should be better able to:Identify practical aspects of using potassium binders for treating hyperkalemia and optimizing GDMT to achieve equitable care for patients with HF and CKDThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.Send us a text about this episode. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/managing-the-burden-of-hyperkalemia-9952SummaryIn this concise CME/CE podcast, a cardiologist and a family physician discuss risks associated with hyperkalemia in patients being treated for heart failure or chronic kidney disease (CKD)—including the risks that accompany down-titration or discontinuation of RAASi therapy.Drs. Javed Butler and Neil Skolnik provide guidance on which patients are most at risk and review the use of potassium binders that can manage hyperkalemia without compromising the crucial use of guideline-directed medical therapy (GDMT). By the end of this podcast episode, listeners will feel much more confident in their ability to safely and effectively address hyperkalemia in patients with heart failure or CKD.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Describe the disparities and clinical implications of hyperkalemia in patients with HF and CKD in terms of optimizing guideline-directed medical therapy (GDMT) and outcomesDiscuss the safety and effectiveness of potassium binders in reducing potassium and optimizing GDMT in patients with HF and CKDThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.Send us a text about this episode. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

High phosphorus (hyperphosphatemia) is a common complication caused by chronic kidney disease. Join us for this NKF Live to learn more about why this happens and how to successfully manage high phosphorus in CKD. During this program, you will hear a kidney doctor, a clinical pharmacist, and a person living with high phosphorus discuss important information to know about when managing high phosphorus.   Dr. Jay Wish is Professor of Clinical Medicine at Indiana University School of Medicine in Indianapolis and Chief Medical Officer for Outpatient Dialysis at Indiana University Health.  He is past president of the National Forum of ESRD Networks, served on the Board of Directors of the Renal Physicians Association and the American Association of Kidney Patients and was the recipient of the latter's Visionary Award in 2005. He has over 150 articles, reviews, and book chapters published, particularly in the areas of ESRD quality oversight/improvement, accountability, anemia management and vascular access. Dr. Katie Cardone is an associate professor at Albany College of Pharmacy and Health Sciences in Albany, NY. She is a clinical pharmacist with a clinical practice and research program focused on improving care in patients with kidney disease in outpatient nephrology and dialysis. She co-led the publication of pharmacy practice standards for pharmacists caring for people with kidney disease. She is a member of the Board of Pharmacy Specialties Ambulatory Care Pharmacy Council and is a fellow of the National Kidney Foundation, the American Society of Nephrology, and the American College of Clinical Pharmacy. Quenton Turner Gee has been on in-center hemodialysis for about 2 years. He was diagnosed with Stage 4 CKD in 2020. After a battle with COVID-19, it quickly progressed to end-stage kidney disease. Since starting on dialysis, he's been advocating for mental health and policies improving access to transplants and kidney innovations.   Additional Resources: Phosphate Lowering Agents High Phosphorus Information NKF Peers   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

On this podcast episode of the top 200 drugs, I'm covering liraglutide, folic acid, clotrimazole, empagliflozin, and semaglutide. Liraglutide is a GLP-1 agonist that can be used for weight loss as well as diabetes. The most common adverse effect of this medication is nausea. Folic acid is a commonly used supplement in pregnancy as well as in those patients taking methotrexate. Deficiency of folic acid can lead to anemia. Clotrimazole is an antifungal agent. It is mostly used for topical purposes such as athlete's foot and vaginal yeast infections. Empagliflozin was originally developed as a diabetes medication but can be helpful in patients with heart failure and CKD. I discuss this in greater detail in the podcast. Semaglutide is another GLP-1 agonist that is used for diabetes care as well as weight loss. The formulation used for diabetes is Ozempic while the weight loss product is Wegovy.

As we step into 2025, this special highlights episode of Diary of a Kidney Warrior Podcast reflects on the incredible journey of 2024. Join Dee Moore, as she recounts the year's most memorable moments, inspiring stories, and impactful lessons from the podcast.   In this episode, we explore: Dee's personal health journey: From an unexpected hospitalisation due to pleural effusion and the transition from peritoneal dialysis to haemodialysis. Peritoneal Dialysis: Features a clip from Episode 104, “An Introduction to Peritoneal Dialysis,” with Consultant Nephrologist Dr Lavanya Kamesh Voices of Encouragement: Highlights of the advice and encouragement from kidney warriors and healthcare professionals. Featuring clips from: Episode 105: “Fez's Kidney Warrior Story: Overcoming Extraordinary Odds. Fez's Transplant Story. Episode 108: “Khiry's Kidney Warrior Story: Overcoming Adversity: A Young Warrior's Battle with Lupus & CKD Episode 110: “Kay's Kidney Warrior Story. A Journey Through Kidney Disease & Pregnancy” Episode 111: “Babies with Kidney Disease: A Mother's Experience of Navigating Uncertainty” Episode 112: “Managing Uncertainty in Chronic Kidney Disease” Episode 114: “Rare Kidney Diseases: Katie's Journey with Loin Pain Haematuria Syndrome” Episode 115: “Overcoming Adversity: A Kidney Warrior's Battle with CKD & Sepsis” Episode 119: Tips and Advice for Haemodialysis. A Nurse's Perspective.” Episode 121: “An Introduction to Home Haemodialysis” Episode 122: “Home Haemodialysis a Patient's Perspective” Episode 124: “Fighting for Safety: Anneka's Kidney Warrior Story & The Safe Lines, Safe Lives Campaign”   Anniversary and Listener Led Q&A Features a clip from Bonus Episode “4 Years of Diary of a Kidney Warrior Podcast: Dee's Exclusive Listener Led Q&A Episode” and Winning the prestigious GX Award for Podcast of the Year. Navigating challenges: How taking a necessary break for her health allowed Dee to return stronger, featuring a clip from the heartfelt Christmas episode: Episode 123, “Finding Hope: Navigating the Christmas Season with Resilience”   This episode is a celebration of the highs, an acknowledgment of the lows, and a testament to the resilience and strength of the kidney warrior community.   Thank you for being a part of this journey. As we embark on another year together, let's continue to uplift, educate, and inspire.   Listen now and relive the moments that made 2024 unforgettable!   For updates and more, follow Dee Moore on:   Instagram: www.instagram.com/diaryofakidneywarrior  Facebook: www.facebook.com/diaryofakidneywarrior  Twitter: www.twitter.com/diaryofakidneyw  Tik Tok: @diaryofakidneywarrior  Youtube: https://www.youtube.com/channel/UChGUfib7lu9eKENlLJ6lafw Linkedin: https://www.linkedin.com/in/dee-moore-diaryofakidneywarrior   Kidney Care UK   https://www.kidneycareuk.org/about-kidney-health/living-kidney-disease/mental-health/   Website: www.kidneycarekuk.org Email: info@kidneycareuk.org Tel: 01420 541 424 Facebook: www.facebook.com/kidneycareuk.org Instagram: @kidneycareuk YouTube: https://www.youtube.com/channel/UCeqQTdAsEzXphqjHVtcTD-A   To sign up to receive the Kidney Matters Quarterly Magazine Email: info@kidneycareuk.org

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sana announces beta cell transplantation without the need for immunosuppresion drugs, Modular Medical teams up with Nudge BG for a brand new completely closed-loop system, the FDA moves forward to crack down on compounded Ozempic and Mounjaro, Dexcom and Abbott bury the legal hatchett for a while, and more.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:     Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Big news from Sana Biotechnology. Their first in human study of islet cells without any immunosuppression appears to be a success. This is very early and hasn't yet been peer reviewed and published.. but after four weeks, there were no safety issues and the transplanted beta cells were producing insulin. Sana's CEO says  “As far as we are aware, this is the first study showing survival of an allogeneic transplant with no immunosuppression or immune-protective device in a fully immune competent individual. Safe cell transplantation without immunosuppression has the potential to transform the treatment of type 1 diabetes and a number of other diseases.”   I've reached out to Sana to get more on this.. love to talk to them soon.   https://www.bakersfield.com/ap/news/sana-biotechnology-announces-positive-clinical-results-from-type-1-diabetes-study-of-islet-cell/article_d0390fd6-99cb-53bd-b04d-9337121e01bf.html XX FDA says no for sotagliflozin as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).  Studies showed a meaningful reduction in A1C but a meaningful increase in DKA. The FDA first rejected this in 2019 and was resubmitted last summer. But The advisory committee voted 11 to 3 against the approval of sotagliflozin stating that the benefits of sotagliflozin do not outweight the risks in adults with T1D and CKD. Sotagliflozin is currently approved under the brand name Inpefa to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with 1) heart failure; or 2) type 2 diabetes mellitus, CKD, and other cardiovascular risk factors.  According to Lexicon, Inpefa will continue to be manufactured and made available to patients. https://www.renalandurologynews.com/news/fda-denies-approval-of-zynquista-for-type-1-diabetes-and-ckd/ XX Two companies we've been following are teaming up.. Modular Medical has an FDA clear patch pump and Nudge BG has an adaptive full closed loop. They've announced a new partnership agreement. From the release: Modular Medical's easy-to-use and cost-effective MODD1 insulin pump technology. Our combined system is intended to nudge blood glucose by making small changes to insulin delivery based on estimated glucose inputs from a continuous glucose monitor." Familiar name to some of you, Lane Desborough is the founder of Nudge BG. He says this will be a fully automated system, no mealtime bolusing needed.   https://www.accesswire.com/957703/modular-medical-announces-licensing-and-partnership-agreement-with-nudge-bg XX Beta Bionics filed for an initial public offering on Monday. The company did not disclose the number of shares it will offer or the price range. Beta Bionics plans for shares to be listed on the Nasdaq under the ticker symbol “BBNX.” The Irvine, California-based company makes an insulin pump called the iLet Bionic Pancreas, which was cleared by the Food and Drug Administration in 2023. Beta Bionics plans to use the proceeds to grow its sales and manufacturing infrastructure and develop new features for its device.   https://www.medtechdive.com/news/beta-bionics-insulin-pump-files-ipo/736805/     XX Tandem Diabetes Care, Inc. signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems.   There's a long history here – UVA is where the Control IQ algorithm was developed.  This agreement seems to keep the team together for another decade. https://www.businesswire.com/news/home/20250107162995/en/Tandem-Diabetes-Care-Enters-Multi-Year-Research-Collaboration-with-UVA-Center-for-Diabetes-Technology-for-Development-of-Advanced-Insulin-Delivery-Systems XX New study says insulin is still the best treatment for gestational diabetes, compared to oral glucose-lowering medications. Metformin and gluburide are being closely looked at since they're easier to administer, less costly, and have better acceptance among patients. But this study says insulin was a bit better – slight more babies were born larger for the metformin group, and more moms had hypoglycemia. https://www.medpagetoday.com/obgyn/pregnancy/113651 XX In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, the type 2 diabetes injection it sells as Victoza. Novo Nordisk last month filed a Citizen Petition with the FDA asking the federal agency to exclude its type 2 diabetes injection Victoza (liraglutide) from a proposed list of drugs eligible for compounding. https://www.biospace.com/fda/novo-launches-citizen-petition-to-block-compounded-victoza XX Bit of an update on compounded terzepatide and semaglutide. The FDA is allowing a grace period of 60 days before starting to enforce the end of allowing compounds of Mounjaro. Meanwhile, semaglutide remains on the FDA's shortage list for several dose strengths, though all doses have been reported as “available” since late October 2024. Compounding pharmacies, especially larger 503B “outsourcing facilities,” maintain they provide an essential public service by offering lower-cost versions of medications that can cost over $1,000 per month. Many insurers still refuse to cover brand-name GLP-1 products for weight loss. Yet  the FDA has reported hundreds of adverse event reports allegedly linked to compounded versions of these drugs, which do not undergo the same rigorous manufacturing inspections and clinical testing as approved brands.   https://www.drugdiscoverytrends.com/compounders-and-drugmakers-clash-over-compounded-weight-loss-drugs-with-fda-in-the-middle/ XX Interesting story here.. this study says a fecal transplant can help people with type 1 and severe gastroenteropathy. The researchers say diabetic gastroenteropathy commonly affects individuals with type 1 diabetes, causing debilitating symptoms like nausea, vomiting, bloating, and diarrhea; however, treatment options remain limited. Researchers conducted a novel clinical trial to test the benefits of FMT in adult patients with type 1 diabetes and severe symptoms of gastroenteropathy, who were randomly assigned to receive either FMT or placebo capsules as the first intervention. After four weeks, Compared with placebo, FMT led to significant changes in the diversity of the gut microbiome. https://www.medscape.com/viewarticle/fmt-shows-early-success-type-1-diabetes-bowel-issues-2025a10000bg XX A couple of weeks ago, listeners told me that the Dexcom geofencing issue we reported on seems to be resolved. Dexcom is now confirming this. Previously, if you had an issue with Dexcom G7 outside of your home country, you couldn't reinstall or use the app without customer support. As of last month, the geofencing issue has now been resolved with the latest Dexcom G7 2.6 app update. Can I travel with my Dexcom G7? | Dexcom XX Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead the U.S. market for CGMs, agreed on Dec. 20 to resolve all outstanding patent disputes and not sue each other over patents for 10 years.   Dexcom and Abbott previously reached a settlement in 2014 related to their diabetes devices, which included a cross-licensing deal and an agreement not to sue each other until 2021. After that agreement expired, the companies filed a volley of patent lawsuits. https://www.medtechdive.com/news/abbott-dexcom-settle-cgm-patent-lawsuits/736300/  

In this powerful and inspiring episode of Diary of a Kidney Warrior Podcast, Dee is joined by Anneka Murphy. Anneka is a Primary School PPA Cover Teacher, a devoted wife, and a mother of four who has been navigating life on dialysis for the past year.   Anneka shares her remarkable Kidney Warrior journey, beginning with her unexpected diagnosis of Chronic Kidney Disease (CKD) Stage 3b following a needle stick injury. Having no prior health issues, Anneka recounts the rollercoaster of medical appointments, emotional challenges, and the impact of CKD on her family, especially her children. She provides heartfelt insights and invaluable advice on managing family dynamics and initiating meaningful conversations with children about chronic illness.   In addition to her personal story, Anneka highlights her advocacy work through the Safe Lines, Safe Lives campaign. Motivated by her own struggles to access essential medical equipment due to cost-cutting measures, Anneka is passionately working to ensure government provision of infection-prevention equipment for all central line patients.   Join us to hear Anneka's lived experiences, the vital lessons she's learned, and the importance of patient advocacy. Discover how you can support her campaign and be inspired by her unwavering resilience and determination.   Tune in now for a heartfelt conversation that offers hope, guidance, and encouragement to everyone navigating life with CKD.   For updates and more, follow Dee Moore on:   Instagram: www.instagram.com/diaryofakidneywarrior  Facebook: www.facebook.com/diaryofakidneywarrior  Twitter: www.twitter.com/diaryofakidneyw  Tik Tok: @diaryofakidneywarrior  Youtube: https://www.youtube.com/channel/UChGUfib7lu9eKENlLJ6lafw Pinterest: https://www.pinterest.co.uk/diaryofakidneywarrior/   Join the Diary of a Kidney Warrior Family Mailing list to get new episode reminders, episode links, Vlogs, newsletters and more!   diaryofakidneywarrior.getform.com/rjv47   WhatsApp   ‎Follow the Diary of a Kidney Warrior Podcast (Kidney Health Podcast) channel on WhatsApp: https://whatsapp.com/channel/0029VaO3ms71iUxipp1eeh2r   Follow Anneka Murphy Facebook: https://www.facebook.com/anneka.n.murphy TikTok: https://www.tiktok.com/@annekamurphkidneywarrior?_t=8sPpyeJVK4X&_r=1   Find Your MP https://members.parliament.uk/FindYourMP   Template letter to copy and paste and use to contact your MP.     Dear My local MP ……………*name, I feel compelled to write as I feel very strongly about this issue. I have recently become aware of a campaign started by a lady in Wakefield West Yorkshire. The “Safe Lines, Safe Lives” campaign. Anneka Murphy is a haemo dialysis patient with a central line to her heart as access for the life saving dialysis needed, until she gets a transplant.  Anneka has recently been informed the shower pouches she uses from Independence direct, that she was getting on prescription, are now stopped due to their cost.  These pouches are essential to prevent the central line from getting wet. It is national guidelines central lines must remain dry to prevent serious infection, but without the appropriate tools how are patients with a line meant to do this?  Anneka has raised this with her MP Jade Botterill who is escalating but support from other MP's would be appreciated. Please raise this with Wes Streeting the health secretary. Patients health is at risk of serious infection without these pouches. All patients in West Yorkshire have been now told these will no longer be issued. This is not just an isolated occurrence as it is happening in pockets all over the country.  Please keep me informed .   Kind regards   ………….*name     Contact Kidney Care UK   •           Website: www.kidneycarekuk.org •           Email: info@kidneycareuk.org •           Tel: 01420 541 424 •           Facebook: www.facebook.com/kidneycareuk.org •           Instagram: @kidneycareuk •           YouTube: https://www.youtube.com/channel/UCeqQTdAsEzXphqjHVtcTD-A   To sign up to receive the Kidney Matters Quarterly Magazine Email: info@kidneycareuk.org  

The FiltrateJoel TopfSwapnil HiremathAC GomezJordy CohenNayan AroraSpecial Guest Brendon NuenEditing bySimon Topf and Nayan AroraShow NotesFINEARTS-HF in NEJM FINEARTS Kidney outcomes in JACCFINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes in Nature Medicine discussion in NephJC BARACH-D: Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial (Nature Medicine)Live Freely Filtered at KidneyWkSwapnil comes out as a SpiroStan post to NephJC TOPCATTOPCAT primary publication TOPCAT North American results TOPCAT funny business explained AHA/ACC/HFSA Heart Failure Guidelines (PDF)SGLT2i are 2aMRA are a 2bARBs are a 2bARNI are a 2bClinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to SpironolactoneKansas city cardiomyopathy questionnaire in patients with CKD without a diagnosis of heart failure: https://pubmed.ncbi.nlm.nih.gov/21187260/GFR slope with steroidal MRAs in HF: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2635Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure? (JACC)Tubular SecretionsSwap: Disclaimer on Apple TVAC: Duo Lingo Plushy (Amazon)Nayan: The Puzzle BoxJordy: Project Hail MaryBrendon has a podcast, The Kidney Compass with Shikha Wadhwani. And he recommends singer-songwriter, Maggie Rogers (YouTube)Joel: The Singularity Is Nearer: When We Merge with AI by Ray KurzweilClosing music, Tim Yau with The Kidney Connection

Many factors can compromise the kidneys' ability to perform the vital work of filtering blood. Decreased kidney function may be the result of common conditions like diabetes or high blood pressure, inherited illnesses such as polycystic kidney disease, or even inflammatory conditions of the kidney. But did you know that nutrition and an improved diet can help those with Chronic Kidney Disease (CKD)? And that U-M Health has specialized renal dietitians to help patients? Meet one of those dietitians, Terrie Holewinski, on the latest episode of The Wrap employee podcast! Holewinski discussed what she loves about her job and gave listeners an inside look at a course she runs called “Kidney Essentials,” which provides patients with CKD information they need to live their lives well. Hosted on Acast. See acast.com/privacy for more information.

IN THIS EPISODE...This episode features Will Stokes, the Co-Founder and Chief Growth & Performance Officer of Strive Health, a leader in value-based kidney care. Strive Health partners with payors, health systems, and providers, utilizing technology and care integration to transform patient journeys from chronic kidney disease to end-stage care, serving over 121,000 patients nationwide.Today's conversation explores Will's journey from biomedical engineering to co-founding Strive Health, its mission to improve chronic kidney disease outcomes, value-based care models, patient-centric solutions, and more.------------Full show notes, guest bio, links to resources mentioned, and other compelling episodes can be found at http://LeadYourGamePodcast.com. (Click the magnifying icon at the top right and type “Will”)Love the show? Subscribe, rate, review, and share! Learn more about us! https://shockinglydifferent.com/-------------WHAT TO LISTEN FOR:1. What is Strive Health's mission in kidney care?2. Who is Will's role at Strive Health?3. How does Strive Health address challenges faced by kidney care patients?4. Why is early detection vital for chronic kidney disease (CKD) management?5. What role do partnerships play in Strive Health's value-based care model?6. How does Strive Health ensure care for patients in rural areas?7. What inspired Will to co-found Strive Health?8. How does Strive Health personalize the patient's experience?9. What are some non-clinical issues Strive Health helps patients manage?10. What does Will identify as the biggest challenge in kidney care?------------FEATURED TIMESTAMPS:[02:39] Will's Background and Personal Life[04:21] Will's Career Journey in Healthcare[07:33] Strive Health's Mission and Approach[09:53] Challenges and Solutions in Kidney Care[13:27] Strive Health's Business Model and Partnerships[18:16] Signature Segment: Will's entry into the LATTOYG Playbook: Patient Experience and Care Management[24:44] Geographic Challenges and Solutions[26:40] Future Goals and Wishes for Kidney Care[28:34] Signature Segment: Will's LATTOYG Tactic of Choice: Leading with Strategic Decision Making[32:01] Connect with Will------------ADDITIONAL RESOURCES FOR YOU:Overview: Our Signature Leadership Development Experience: http://bit.ly/DevelopYourGame

Episode Title: "Gut, Kidneys, and Kibble: CKD Insights with Dr. Jessica Quimby"In this episode of the Purr Podcast, Dr. Jolle Kirpensteijn and Dr. Susan Little are joined once again by feline chronic kidney disease (CKD) expert, Dr. Jessica Quimby. Together, they unpack some of the latest insights into managing this complex condition in cats.We dive into key topics, including:The role of AST-120 in managing CKD and its impact on the gut-kidney axis.Dietary strategies, focusing on phosphorus control and how it can help manage CKD progression.The importance of understanding the gut-kidney connection and how it influences overall health.A surprising finding: decreased defecation frequency in CKD cats and how missing litterbox days can be a symptom worth addressing.Appetite challenges in CKD cats—how to recognize and manage reduced food intake.Anemia in CKD cats.This episode is packed with practical advice, fascinating discoveries, and plenty of feline-friendly discussion. Whether you're a vet, a cat owner, or just a fan of the mysterious ways of our feline friends, you'll come away with valuable insights to help CKD cats live their best lives.

The Filtrate:Joel TopfSwapnil HiremathWith Special Guest:Michelle Hladunewich, Nephrologist at the University of TorontoMir Melamed, Maternal-Fetal Medicine at the University of TorontoEditor Simon TopfShow NotesPriscilla Smith's letter:Dear Joel and the Freely Filtered team,I am a long-time fan of your podcast and was looking forward to hearing your recently aired discussion of the Praecis study of sflt1:PlGF use in preeclampsia. Preeclampsia and renal disease in pregnancy are areas that many nephrologists report a lack of knowledge or confidence in discussing and managing. I am a nephrologist who has been co-leading a renal pregnancy clinic in London while writing a PhD on progression of renal disease in pregnancy. I have had the immense privilege of working with experts and key opinion leaders in preeclampsia research both in the UK and internationally. As you know, preeclampsia is a serious and significant condition contributing to global maternal mortality and is also associated with future CKD and CVD risk so is both relevant and important within our professional group.Sadly, I found myself disappointed by the episode and felt it was a missed opportunity. I appreciate that you had difficulties obtaining appropriate experts to join the discussion, but perhaps it would have been better to delay production. While you all valiantly proceeded to discuss this important study, the topic is complex and there appeared to be a lack of understanding of the surrounding literature and pathogenesis of preeclampsia. Sadly, the maternal medicine expert's comments at the end of the podcast added little as she seemed determine to negate any benefit from the results despite declaring she had no experience or expertise in the use of these biomarkers.There are many people who understand the clinical aspects of preeclampsia as well as having direct experience of the use and utility of these biomarkers who would have been able to contribute much to your conversation. I look forward to future discussions of renal disease in pregnancy on your podcast and would be happy to suggest some expert panellists if you ever find yourself stuck.Kind regards,Priscilla Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia (JCI 2003)sFlt background: Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta (PubMed)PlGF background: Perspectives on the Use of Placental Growth Factor (PlGF) in the Prediction and Diagnosis of Pre-Eclampsia: Recent Insights and Future Steps (PubMed)The PRAECIS trial (NephJC | NEJM Evidence)

The following question refers to Sections 7.3.3 and 7.3.6 of the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure.The question is asked by Palisades Medical Center medicine resident & CardioNerds Academy Fellow Dr. Maryam Barkhordarian, answered first by UTSW AHFT Cardiologist & CardioNerds FIT Ambassador Dr. Natalie Tapaskar, and then by expert faculty Dr. Robert Mentz.Dr. Mentz is associate professor of medicine and section chief for Heart Failure at Duke University, a clinical researcher at the Duke Clinical Research Institute, and editor-in-chief of the Journal of Cardiac Failure. Dr. Mentz has been a mentor for the CardioNerds Clinical Trials Network as lead principal investigator for PARAGLIDE-HF and is a series mentor for this very Decipher the Guidelines Series. For these reasons and many more, he was awarded the Master CardioNerd Award during ACC22.The Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders Dr. Amit Goyal and Dr. Dan Ambinder, with mentorship from Dr. Anu Lala, Dr. Robert Mentz, and Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance.Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. American Heart Association's Scientific Sessions 2024As heard in this episode, the American Heart Association's Scientific Sessions 2024 is coming up November 16-18 in Chicago, Illinois at McCormick Place Convention Center. Come a day early for Pre-Sessions Symposia, Early Career content, QCOR programming and the International Symposium on November 15. It's a special year you won't want to miss for the premier event for advancements in cardiovascular science and medicine as AHA celebrates its 100th birthday. Registration is now open, secure your spot here!When registering, use code NERDS and if you're among the first 20 to sign up, you'll receive a free 1-year AHA Professional Membership! Question #39 Ms. Kay Lotsa is a 48-year-old woman with a history of CKD stage 2 (baseline creatinine ~1.2 mg/dL) & type 2 diabetes mellitus. She has recently noticed progressively reduced exercise tolerance, leg swelling, and trouble lying flat. This prompted a hospital admission with a new diagnosis of decompensated heart failure. A transthoracic echocardiogram reveals LVEF of 35%. Ms. Lotsa is diuresed to euvolemia, and she is started on carvedilol 25mg BID, sacubitril/valsartan 49-51mg BID, and empagliflozin 10mg daily, which she tolerates well. Her eGFR is at her baseline of 55 mL/min/1.73 m2 and serum potassium concentration is 3.9 mEq/L. Your team is anticipating she will be discharged home in the next one to two days and wants to start spironolactone. Which of the following is most important regarding her treatment with mineralocorticoid antagonists?ASpironolactone is contraindicated based on her level of renal impairment and should not be startedBSerum potassium levels and kidney function should be assessed within 1-2 weeks of starting spironolactoneCEplerenone confers a higher risk of gynecomastia than does spironolactoneDThe patient will likely not benefit from initiation of spironolactone if her cardiomyopathy is ischemic in origin Answer #39 ExplanationThe correct answer is B – after starting a mineralocorticoid receptor antagonist (MRA), it is important to closely monitor renal function and serum potassium levels.MRA (also known as aldosterone antagonists or anti-mineralocorticoids) show consistent improvements in all-cause mortality, HF hospitalizations, and SCD across a wide range of patients with HFrEF.

In episode 590, Mike and James talk in a PREMIUM way about a new trial that looked at the question, does depression screening provide any benefit in primary care? We also go over a case-finding publication on screening for asthma/COPD. At the end we look at, does implementing guideline care improve outcomes for CKD? The […]